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Abstract Poor dyspnoea perception in asthmatic patients seems to be associated with increased risk of asthma
exacerbation.We have studied the relationship between baseline dyspnoea perception and in£ammatory markers in
sputumineightpatientswithmild asthma andin13 patientswithmoderateto severe asthma.Theperceptionof dyspnoea
was scored on the Borg scale.Eosinophilic cationic protein (ECP) wasmeasured by £uoroimmunoassay and by an inter-
leukin (IL)-5 sandwich ELlSA.The baseline Borg score was signi¢cantly higher in patients with severe asthma than in
patientswithmild tomoderate asthma (4?170?29 vs. 2?2870?28, Po0?05).The proportion of eosinophil and ECPlevels
in the sputum were signi¢cantly higher in patients with moderate to severe asthma. IL-5 in sputum was signi¢cantly
increased inmoderate to severe asthmatic patients compared tomild asthmatic patients. A signi¢cant relationshipwas
found betweenthe baseline perception score and FEV1/FVC (r=0?53, Po0?01), sputumeosinophils (r= 0?70, Po0?01)
and sputum ECP (r= 0?62, Po0?01).These ¢ndings suggestthatthe baseline perception score is related to in£ammatory
markers in sputum, and that the perception of dyspnoea aswell as airway in£ammatorymarkersmay be considered to
evaluate asthma severity.r2002 Elsevier Science Ltd
doi:10.1053/rmed.2001.1248, available online at http://www.idealibrary.comon
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Bronchial asthma is de¢ned as a chronic in£ammatory
disorder of the airways in which many cells and cellular
elements play a role. In particular, mast cells, eosinophils,
T lymphocytes, neutrophils and epithelial cells have been
implicated. In susceptible individuals, this in£ammation
causes recurrent episodes of wheezing, breathlessness,
chest tightness and cough, particularly at night and in
the earlymorning (1).
Patients with severe asthma seem to have a reduced
ability to perceive air£owobstruction.Perception ofdys-
pnoea duringbreathing through a series of tubeswith in-
creasing resistance was signi¢cantly decreased in
patients with a history of near-fatal asthma attacks, as
comparedwithpatientswhohad asthma of similar sever-
ity but no history of such attacks (2,3). The authors re-
ported that inhalation of a short-acting b2-agonist
decreased dyspnoea, but increased the perception of
dyspnoea induced by a resistive load in patients withReceived 25 February 2001and accepted in revised from 2October
2001.
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Fax: 82-062-382-3540; E-mail: jas877@chollian.netasthma (4). Markers of airway in£ammation in induced
sputum were correlated with clinical and physiological
variables (5,6).
In the present study we hypothesized that airway in-
£ammation in patients with asthma may in£uence per-
ception of dyspnoea. The aim of this study was
therefore to evaluate the relationship between the per-
ception of dyspnoea and in£ammatory markers in spu-
tum.
METHODS
Subjects
Twenty-one patients with asthma were enrolled for this
study (Table1).The diagnoses of asthmawere established
in the patients by their symptoms of recurrent episodic
wheezing, cough and/or dyspnoea, accompanied either
bymethacholine airwayhyper-responsiveness orby a sig-
ni¢cant improvement of forced expiratory volume in
1sec (FEV1) (15%) following anti-asthma therapy.The se-
verity of asthma (8) was classi¢ed according to current
symptoms (cough, wheeze, dyspnoea), prescribed asth-
ma medication and results of methacholine provocation
test. Sixteen patients were hyper-responsive to inhaled
methacholine as shown by a provocative concentration
TABLE 1. Modi¢ed Borg scale
0 nothingat all (just noticeable)
0?5 very very slight
1 very slight
2 slight
3 moderate
4 somewhat severe
5 severe
6
7 very severe
8
9 very very severe (almostmaximal)
10 maximal
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vere asthma consisted of six patients who had two or
more exacerbations during the preceding year requiring
treatmentwith oral corticosteroids despitehigh-dosein-
haled corticosteroid therapy (budesonide 800mg twice
daily or £uticasone propionate 500mg twice daily). The
patients with moderate asthma consisted of seven pa-
tients who had inhaled high dose corticosteroid therapy
(budesonide 800mg twice daily or £uticasonepropionate
250mg twice daily). The patients were recruited from
ouroutpatient allergydepartment.Mostof themhadvis-
ited our hospital formany years, mostly on a 3^6month
basis and during exacerbations. Inhaled corticosteroids
wereroutinely tapered to lowestpossible doses. All sub-
jects had inhaled short-acting b2-agonists on demand as
rescue medication. The subjects ware studied prior to
corticosteroid treatment during an exacerbation. No
subject had respiratory infection for 4 weeks prior to
the study. All subjectswere informed andgave their con-
sent before starting the study.The ethics committee of
our hospital approved the study protocol.
Scoring of dyspnoea
The scoring of dyspnoea perception on admission was
measured using a modi¢ed Borg scale (9).This is a linear
scale of the numbers ranking themagnitude of di⁄culty
in breathing, ranging from 0 (none) to 10 (maximal)
(Table1).
Bronchial hyper-responsiveness
Methacholine challenge testswere carriedoutby amod-
i¢edmethod described by Chaiet al. (10).Concentrations
of 0?075, 0?15, 0?31, 0?62, 1?25, 2?5, 5, 10 and 25mgml1
methacholine were prepared by dilution with bu¡ered
saline. AMicro-dosimeter (S&M Instrument Co, Doyles-
town, PA,U.S.A.) was used to deliver the aerosol gener-
ated by a DeVilbiss 646 nebulizer. Subjects inhaled ¢ve
breaths of increasing concentrations ofmethacholineun-til FEV1 fell by more than 20% of its basal value or the
highest concentration was reached. The higher value of
these FEV1at (30 or 90 and180 sec after each inhalation)
was adopted for analysis.
Sputum induction andprocessing
Sputumwas induced only when it could not be produced
spontaneously.The sputum induction was performed as
a modi¢cation of themethod describedby Fahy et al. (11)
All subjectswerepremedicatedwith twopu¡s of inhaled
salbutamol (200mg). Subjects inhaled 3% hypertonic sal-
ine solution aerosols generated by a ultrasonic nebulizer
(NE-U03, OMRON Co., Tokyo, Japan) with maximum
output of 0?15^0?3mlmin1 and mass median aerody-
namic diameter of 4?5mm.Hypertonic salinewas inhaled
for 25^30min according to the severity of asthma until
adequate volume of sputum was expectorated. They
were instructed to cough the sputum into a sterile plas-
tic container. The volumes of samples and duration of
sputum induction were recorded. FEV1 was measured
before, during and after induction of sputum. Sputum in-
duction was stopped in subject with a fall of the FEV1
15%.
Sputumwas selected from saliva andprocessedwithin
2h.Themethod of sputumexamination describedby Po-
pov et al. (12) was modi¢ed. Sputumwas treated by add-
ing equal volumes of 0?1% dithiothreitol (Sputalysin 10%;
Gibco BRL,U.S.A.) followedby equal volumes of Dulbec-
co’s phosphate-bu¡ered saline (D-PBS). The sample was
then mixed gently and placed in a shaking water bath at
371C for15min to ensure complete homogenization.The
sample was removed from the water-bath periodically
for further brief gentle mixing. The suspension was ¢l-
tered through a gauze (1mm pore size), the ¢ltrate was
centrifuged at 1500 rpm for 10min and the supernatant
was aspirated and stored in Eppendorf tubes at 701C
for later assay. The cell pellet was resuspended in D-
PBS,1000ml and total non-squamous cells were counted
in a modi¢ed Neubauer haemocytometer. The cell sus-
pension was adjusted to 0?5105 ml1 and then 50ml of
cell suspension was placed into cups of Sakura cytocen-
trifuge (Model CF-127, Tokyo, Japan). Two coded cytos-
pins were prepared at 600 rpm for 5min, air-dried and
stainedbyDi¡-Quick (Kookje Scienti¢c Products, Japan)
stain. Cell di¡erentials of 400 non-squamous cells were
performed inDi¡-Quick stain slidesby two investigators
who did not know the subject’s history, and results were
expressed as a percentage of the total non-squamous
cell count.
ECP and IL-5 measurement
The concentration of ECP in 400ml in the supernatant of
induced sputumwas determined using £uoroimmunoas-
FIG. 1. The baseline Borg score in patientswith asthma. Hori-
zontalbar indicatesmeanvalue. *Po0?01.
FIG. 2. The correlation between FEV1/FVC and baseline per-
ception score of dyspnoea. *Po0.01. Patients with mild (&),
moderate (~), and severe (*) asthma.
152 RESPIRATORYMEDICINEsay (UniCAP system). IL-5 wasmeasured by quantitative
sandwich enzyme immunoassay (QuantikineTM; R&D
Systems, Inc., MN,U.S.A.) as described by Dickason (13).
Samples were analysed in duplicate.The limits of detec-
tion for ECP and IL-5 assayswere 2?0mgl1and 3pgml1,
respectively.
Blood sampling
Venous blood was collected tubes containg 5?0ml ethy-
lenediaminetetraacetic acid (K3 Vacutainer BD, Ruther-
fold, NJ, U.S.A.) before sputum induction. Di¡erentiaI
white blood cell count was obtained with use of a Coul-
ter STKS instrument (Coulter Corp.,Hialeah, FL,U.S.A.)
StatisticaI analysis
All data were analysed using the SPSS version 7?5 for
Windows. Data are expressed as mean7SEM. We used
the Mann^WhitneyU-test for unpaired data to perform
statistical analysis. Spearman’s correlations with non-
normal distributions were used to assess relationships
between variables. A P-value ofo0?05 was considered
signi¢cant.
RESULTS
The characteristics of the subjects including demo-
graphics, asthma severity are shown in Table 2. The
baseline Borg score was signi¢cantly higher in patients
with severe asthma than patients withmild tomoderate
asthma (2?2870?28 vs. 4?170?29, Po0?05; Fig. 1)
The proportion of eosinophil and ECP level in sputum
were signi¢cantly higher in patients with moderate to
severe asthma compared to those with mild asthma
(5?471?3% vs. 38?575?6%, Po0?01; 208?5752?0mgl1TABLE 2. Characteristics of patientswith asthma
Mild Moderate to severe
Subjects (n) 8 13
Age (Years) 37?274?1 38?771?5
Sex (M/F) 4/4 7/6
Smoker (ex) 1 (0) 3 (3)
IgE (IUml1) 26?7728?2 655?6758?4
Atopic (n) 3 7
PC20 (mgd
1)w 4?2371?34 1?3070?59 (n= 8)
FEV1 (%pred) 82?874?7 62?572?9*
FCV (%pred) 82?475?1 74?273?6
FEV1/FCV (%) 93?273?5 59?272?6*
Data expressed asmean7SEM
*Po0?01.
wPC20: provocation concentration of methacholine produ-
cinga 20% fall of FEV1.vs. 15107253?5mgl1, Po0?01). IL-5 in sputum was
signi¢cantly higher in patients with moderate to
severe asthma compared to patients with mild asthma
(32?276?5pgml1 vs. 0 pgml1). A signi¢cant relation-
ship was found between the baseline perception score
and FEV1/FVC (r=0?53, Po0?01; Fig. 2) as well as be-
tween baseline perception score and both sputum eosi-
nophil percentage (r=0?70, Po0?01; Fig. 3) and sputum
ECP (r=0?62, Po0?01). However, no relationship was
found between baseline perception score and serum eo-
sinophils or serum ECP.
DISCUSSION
This study has demonstrated that the dyspnoea percep-
tion score is related to in£ammatorymarkers in sputum,
which suggests that the perception of dyspnoea as well
as airway in£ammatory markers may be considered to
evaluate the clinical severity of asthma.
Poor perception in asthmamay lead to a delay in start-
ing appropriate asthma treatment,which is probablyone
of the key factors contributing to death from asthma
FIG. 3. (a) The correlationbetweensputumeosinophils andbaselineperceptionofdyspnoea. *Po0?01. (b) The correlationbetween
sputum ECPandbaseline of dyspnoea. *Po0?01.Patientswithmild (&), moderate (~), and severe (*) asthma.
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tion of acutely inducedbronchoconstriction (15), and less
severe breath lessness induced by inspiratory loads, was
detected in near fatal attack patients (16).We have also
reported that inhalation of a short-acting b2-agonist
treatmentdecreases dyspnoea, but increases perception
of dyspnoea induced by a resistive load in patients with
asthma (4).
The severity of dyspnoea is shown to be greater in re-
sponse to hypertonic saline as compared with metha-
choline at the same reduction of FEV1 (17), which might
be explained by di¡erences in perception due to in£am-
matory activity within the airways (17,18). An association
between perception of breathlessness and airway in-
£ammation has previously been reported, as measured
by eosinophilic in¢ltration and epithelial shedding in
bronchial biopsies from patients with asthma (19). How-
ever, there have been no published data comparing base-
line perception scorewith airway in£ammation markers
in sputum. In the present study, the baseline Borg score
was signi¢cantly higher in patients with severe asthma
compared with patients with mild to moderate asthma.
According to asthma severity, the proportion of eosino-
phil and ECP levels in sputumwere signi¢cantly increased
inpatientswithmoderate to severe asthma than in those
of mild asthma. IL-5 in sputum was also signi¢cantly in-
creased in moderate to severe asthmatic patients com-
pared to mild asthmatic patients.These results support
the idea that awareness of perception of dyspnoea is cor-
related with sputum in£ammatorymarkers, and that in-
creased eosinophilic in£ammation is associated with
more pronounced dyspnoea score. Further studies are
needed to evaluate the relationship between perception
score and in£ammatorymarker changes after Iong-term
anti-in£ammatory controlmedication.
in’t Veen et al. (20) reported that increased sputum
eosinophilia is an indicator of clinical instability, and
that eosinophilic airways in£ammation might a¡ect dys-
pnoea perception in severe asthma. In this study the
proportion of eosinophil in sputum was increased in
patients with severe asthma, suggesting that sputumeosinophilsmightbe avaluablemarker of clinical severity
in asthma. Roisman et al. (19) reported that perception
of bronchoconstriction in asthmatic patients is related
to eosinophilic in£ammation and to epithelial damage
in airways, and that corticosteroid treatment is asso-
ciatedwith improvedperception of bronchoconstriction
induced by bradykinin. The sensation of dyspnoea
was also found to be signi¢cantly related to the FEV1
and the speci¢c inspiratory resistance in the asthmatics
(21).This study shows a signi¢cant relationship between
the baseline perception score and FEV1/FVC, sputum eo-
sinophils and sputumECP,which is in agreementwith the
results of Roisman et al. (19). This study shows that per-
ception of breathlessness associated with bronchocon-
striction may be in£uenced by the degree of
eosinophilic in¢ltration, which is related to the clinical
severity of asthma.
Low baseline FEV1 and high bronchial responsiveness
are associated with a low degree of ‘perceptiveness’ for
bronchoconstriction, suggesting that patients with a
more severe degree of asthma either show adaptation
of ‘perceptiveness’ for airway obstruction or that low
perceptiveness leads to more severe asthma. Although
asthmatic patients poorly perceive dyspnoea, dyspnoea
perception is related to in£ammatory markers (22).
Therefore, we suggest that the perception of dyspnoea
may be considered in evaluating of clinical severity of
asthma.
The degree of in£ammation in airways as well as
asthma severity depends on the anti-in£ammmatory
load. Anti-leukotrienes and inhaled corticosteroidmight
a¡ect the perception di¡erently depending on di¡erent
targeting and mechanism of action, and possibly side-ef-
fects. In this study the e¡ectof sputumon anti-in£amma-
tory therapy was small because sputum induction was
studied before corticosteroid therapy.
In conclusion, we found that the baseline perception
score is related to in£ammatorymarkers in sputum, sug-
gesting that theperception of dyspnoea aswell as airway
in£ammatory markers may be considered to evaluate
the clinical severity of asthma.
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